The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

The PRESTO trial evaluated adding apalutamide (APA) and abiraterone (Abby) to a standard LHRH analog. The triplet combination arm demonstrated increased toxicity without any additional efficacy gains compared to the doublet arm (LHRH + APA). This finding reinforces that more intensive combination therapy is not always better and can be detrimental in this setting.

A key lesson from radium-223 trials is the critical need for concurrent bone protective agents. Protocol amendments adding these agents eliminated an excess of osteoporotic fractures. This requires only osteoporosis prevention dosing (e.g., yearly zoledronic acid), not the more frequent dosing used for skeletal-related events.

The SUNRISE 2 trial's chemoradiation arm showed unexpectedly strong results. This is likely due to a protocol requiring a repeat resection (RIT-URBT) before randomization, which weeded out aggressive tumors and selected a patient population with a better prognosis, making the control arm unusually difficult to beat.

The common practice of switching from one ARPI to another upon disease progression is now considered ineffective for most patients. With the advent of proven alternatives like chemotherapy and lutetium, using an "ARPI switch" as the sole control arm in clinical trials is no longer ethically or scientifically sound.

If lutetium-PSMA is approved and used upfront in hormone-sensitive disease, clinicians may become more comfortable with radioligands generally. This could lead them to use the enzalutamide-radium combination more frequently later on, paradoxically increasing radium's use by flipping the current treatment sequence.

Clinicians may be biased towards lutetium-PSMA because it causes significant PSA drops, which radium-223 does not. This observable metric may not reflect superior overall efficacy, as radium's survival benefit is proven and it may even have unique synergistic potential with drugs like enzalutamide through different biological pathways.

Recent phase 3 trial data highlights a significant gap in care for metastatic castration-resistant prostate cancer (mCRPC). Despite clear guideline recommendations, only about half of patients in the trial received bone-targeted agents, exposing a concerning real-world trend of underutilization of standard-of-care supportive therapy.

The BRCA-Way trial showed a combination of abiraterone and olaparib was effective. However, its relevance is limited as many patients now receive abiraterone upfront. The next-generation TALENT trial is designed specifically to address this, testing if re-challenging with an AR-pathway inhibitor alongside a PARP inhibitor is beneficial, demonstrating how trial design must constantly evolve to answer questions raised by new standards of care.